King Pharmaceuticals (NYSE: KG), the world's 39th largest pharmaceutical company, is based in Bristol, Tennessee. King produces a wide range of pharmaceuticals, including Altace for heart attack prevention, Levoxyl for hypothyroidism, Sonata, a sleeping aid, and Skelaxin, a muscle relaxant. King Pharmaceuticals currently operates manufacturing facilities in Bristol, Tennessee, Rochester, Michigan, St. Louis, Missouri, St. Petersburg, Florida, and Middleton, Wisconsin, and they employ approximately 2700 people including a sales force of over 1000 individuals.
Figures are based on itemized contributions reported to the Federal Election Commission and state agencies. Please note that:
- contributions under $200 are not reported, and so are not included in totals.
- only contributions from individuals and organizations to candidates are included. Various accounting measures and more exotic contribution types are excluded.
- contributions are matched based on organization and recipient name reported within each election cycle. Contributions using an incorrect or non-standard version of the name may be missed.
- corporate name changes and mergers may cause figures to differ from those of the Center for Responsive Politics.
- organization totals include known subsidiaries of the organization.
Latest FEC Datacovers through committee's April 8, 2011 filing.
Summaryoverview of the committee's finances
- Total Raised:
- Total Spent:
- Cash on Hand:
Standardized Donation Informationcovers roughly through Q4 2012. may lag behind FEC section above, as donors and industries are identified by hand.
- Employee Color Block
- PAC Color Block
Republicans vs. Democratsin dollars
State vs. Federalin dollars
Top PAC Recipients
- Employee Color Block
- PAC Color Block
RegulationsMentioned in 20 dockets
All data is based on documents downloaded from Regulations.gov. The first table shows mentions: all documents that include the name of the company anywhere in the document or document metadata. The second table shows submissions: all documents where the submitter metadata included the company name. Each table shows the top 10 dockets, ranked by number of occurrences.
Matches are based on a search for the company name. Variations in the company name, such as acronyms, nicknames or alternate names may cause documents to be missed. The mention of a company name in a document may be incidental and does not necessarily indicate that the company has any relevance to the document. Company names that are common English words may erroneously match with text that is not referring to the company.
Not all agencies submit public comments to Regulations.gov. For a list of participating and non-participating agencies see here. Agencies that do submit to Regulations.gov have varying levels of accuracy and completeness.
Regulations and public comments can be downloaded in bulk here.
The tables show occurrences of "King Pharmaceuticals" in public comments on proposed federal regulations.
Mentions in Document Text
View all mentions data for King Pharmaceuticals
- Toggle 13 FDA Impact of Approved Drug Labeling on Chronic Opioid Therapy; Public Hearing; Request for Comments 2012
- Toggle 2 FDA Refuse to Approve King's Remoxy NDA Unless the Conditions Specified in the Petition are Satisfied - CLOSED 2011
- Toggle 2 FDA Request That the Food and Drug Adminstration Make a Determination That OxyContin (Oxycodone Hydrochloride Extended-Releases) Tablets, 10 mg, 15 mg, 20 mg, 40 mg, 60 mg, 80 mg and 160 mg Withdrawn From Sale for Reasons Other Than Safety or Effectiveness 2011
- Toggle 2 FDA Determine whether Chloramphenicol Capsules 250 mg was withdrawn from sale for reasons other than safety or effectiveness and grant permission to relist application number A060851 - CLOSED 2011
- Toggle 1 CMS Medicaid Program; Covered Outpatient Drugs (CMS-2345-P) 2012
- Toggle 1 CMS Medicare Program; Payment Policies Under the Physician Fee Schedule and Other Revisions to Part B for CY 2012 2011
- Toggle 1 EPA State of Tennessee; Underground Injection Control (UIC) Program Primacy 2011
- Toggle 1 FDA Refrain From Approving an ANDA From Relying on Oxecta as a Reference Listed Drug (RLD) unless the Proposed Product Incorporate Same Inactive Ingredients 2012
- Toggle 1 FDA Declare the Drug Products, Bortezomib for Injection, 1mg and 2.5 mg, are Suitable for Consideration in an Abbreviated New Drug Application (ANDA) 2012
- Toggle 1 FDA Designate Oxecta™ (Oxycodone Hydrochloride)Tablets, NDA 202080, as a Second Reference Listed Drug Product for the Purpose of Submitting an Abbreviated New Drug Application 2011